135 related articles for article (PubMed ID: 32839509)
1. FAM83H-AS1 is a potential modulator of cancer driver genes across different tumors and a prognostic marker for ER/PR + BRCA patients.
Ríos-Romero M; Cedro-Tanda A; Peña-Luna M; Mancera-Rodríguez MA; Hidalgo-Pérez L; Cisneros-Villanueva M; Beltrán-Anaya FO; Arellano-Llamas R; Jiménez-Morales S; Alfaro-Ruíz LA; Tenorio-Torres A; Domínguez-Reyes C; Villegas-Carlos F; Ochoa-Mendoza E; Hidalgo-Miranda A
Sci Rep; 2020 Aug; 10(1):14145. PubMed ID: 32839509
[TBL] [Abstract][Full Text] [Related]
2. Serum LncRNA-ATB and FAM83H-AS1 as diagnostic/prognostic non-invasive biomarkers for breast cancer.
El-Ashmawy NE; Hussien FZ; El-Feky OA; Hamouda SM; Al-Ashmawy GM
Life Sci; 2020 Oct; 259():118193. PubMed ID: 32763293
[TBL] [Abstract][Full Text] [Related]
3. LncRNA FAM83H-AS1 contributes to the radioresistance, proliferation, and metastasis in ovarian cancer through stabilizing HuR protein.
Dou Q; Xu Y; Zhu Y; Hu Y; Yan Y; Yan H
Eur J Pharmacol; 2019 Jun; 852():134-141. PubMed ID: 30831080
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of FAM83H-AS1 indicates poor patient survival and knockdown impairs cell proliferation and invasion via MET/EGFR signaling in lung cancer.
Zhang J; Feng S; Su W; Bai S; Xiao L; Wang L; Thomas DG; Lin J; Reddy RM; Carrott PW; Lynch WR; Chang AC; Beer DG; Guo YM; Chen G
Sci Rep; 2017 Feb; 7():42819. PubMed ID: 28198463
[TBL] [Abstract][Full Text] [Related]
5. LncRNA FAM83H-AS1 promotes triple-negative breast cancer progression by regulating the miR-136-5p/metadherin axis.
Han C; Fu Y; Zeng N; Yin J; Li Q
Aging (Albany NY); 2020 Feb; 12(4):3594-3616. PubMed ID: 32074085
[TBL] [Abstract][Full Text] [Related]
6. LncRNA FAM83H-AS1 promotes oesophageal squamous cell carcinoma progression via miR-10a-5p/Girdin axis.
Feng B; Wang G; Liang X; Wu Z; Wang X; Dong Z; Guo Y; Shen S; Liang J; Guo W
J Cell Mol Med; 2020 Aug; 24(16):8962-8976. PubMed ID: 32583631
[TBL] [Abstract][Full Text] [Related]
7. FAM83H-AS1 is upregulated and predicts poor prognosis in colon cancer.
Yang L; Cui J; Wang Y; Tan J
Biomed Pharmacother; 2019 Oct; 118():109342. PubMed ID: 31545230
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance.
Da J; Liu P; Wang R; Bu L
Pathol Res Pract; 2019 Oct; 215(10):152616. PubMed ID: 31493939
[TBL] [Abstract][Full Text] [Related]
9. Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway.
Wang B; Guan G; Zhao D
Biomed Pharmacother; 2020 May; 125():109961. PubMed ID: 32028241
[TBL] [Abstract][Full Text] [Related]
10. Long non-coding RNA FAM83H-AS1 acts as a potential oncogenic driver in human ovarian cancer.
Yuan X; Huang Y; Guo M; Hu X; Li P
J Ovarian Res; 2021 Jan; 14(1):6. PubMed ID: 33413565
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of lncRNA FAM83H-AS1 in ovarian cancer.
Gong YB; Zou YF
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4656-4662. PubMed ID: 31210291
[TBL] [Abstract][Full Text] [Related]
12. FAM83H-AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma.
Wang S; Han C; Liu T; Ma Z; Qiu M; Wang J; You Q; Zheng X; Xu W; Xia W; Xu Y; Hu J; Xu L; Yin R
Clin Transl Med; 2021 Feb; 11(2):e316. PubMed ID: 33634993
[TBL] [Abstract][Full Text] [Related]
13. LINC00460 Is a Dual Biomarker That Acts as a Predictor for Increased Prognosis in Basal-Like Breast Cancer and Potentially Regulates Immunogenic and Differentiation-Related Genes.
Cisneros-Villanueva M; Hidalgo-Pérez L; Cedro-Tanda A; Peña-Luna M; Mancera-Rodríguez MA; Hurtado-Cordova E; Rivera-Salgado I; Martínez-Aguirre A; Jiménez-Morales S; Alfaro-Ruiz LA; Arellano-Llamas R; Tenorio-Torres A; Domínguez-Reyes C; Villegas-Carlos F; Ríos-Romero M; Hidalgo-Miranda A
Front Oncol; 2021; 11():628027. PubMed ID: 33912452
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA FAM83H-AS1 is regulated by human papillomavirus 16 E6 independently of p53 in cervical cancer cells.
Barr JA; Hayes KE; Brownmiller T; Harold AD; Jagannathan R; Lockman PR; Khan S; Martinez I
Sci Rep; 2019 Mar; 9(1):3662. PubMed ID: 30842470
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between the ER pathway and the lncRNA MAFG-AS1/miR-339-5p/ CDK2 axis promotes progression of ER+ breast cancer and confers tamoxifen resistance.
Feng J; Wen T; Li Z; Feng L; Zhou L; Yang Z; Xu L; Shi S; Hou K; Shen J; Han X; Teng Y
Aging (Albany NY); 2020 Oct; 12(20):20658-20683. PubMed ID: 33098638
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA FAM83H-AS1 exerts an oncogenic role in glioma through epigenetically silencing CDKN1A (p21).
Bi YY; Shen G; Quan Y; Jiang W; Xu F
J Cell Physiol; 2018 Nov; 233(11):8896-8907. PubMed ID: 29870057
[TBL] [Abstract][Full Text] [Related]
17. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
18. FAM83H-AS1 is associated with clinical progression and modulates cell proliferation, migration, and invasion in bladder cancer.
Shan H; Yang Y; Zhu X; Han X; Zhang P; Zhang X
J Cell Biochem; 2019 Mar; 120(3):4687-4693. PubMed ID: 30537032
[TBL] [Abstract][Full Text] [Related]
19. A Novel Androgen-Induced lncRNA FAM83H-AS1 Promotes Prostate Cancer Progression
Liu B; Qian D; Zhou W; Jiang H; Xiang Z; Wu D
Front Oncol; 2020; 10():620306. PubMed ID: 33614501
[TBL] [Abstract][Full Text] [Related]
20. The clinical prognostic value of lncRNA FAM83H-AS1 in cancer patients: a meta-analysis.
Yang Q; Wang J; Zhong P; Mou T; Hua H; Liu P; Xie F
Cancer Cell Int; 2020; 20():72. PubMed ID: 32165862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
